Sensitization of restraint-induced corticosterone secretion after chronic restraint in rats: involvement of 5-HT₇ receptors.

Publisher: Pergamon Press Country of Publication: England NLM ID: 0236217 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7064 (Electronic) Linking ISSN: 00283908 NLM ISO Abbreviation: Neuropharmacology Subsets: MEDLINE

Publication: Oxford : Pergamon Press
Original Publication: Oxford, New York, Pergamon.

Disease Models, Animal* ; Up-Regulation*/drug effects; Corticosterone/*metabolism ; Hypothalamo-Hypophyseal System/*metabolism ; Pituitary-Adrenal System/*metabolism ; Receptors, Serotonin/*metabolism ; Stress, Psychological/*metabolism; Adrenal Cortex/drug effects ; Adrenal Cortex/metabolism ; Adrenal Cortex/pathology ; Adrenocorticotropic Hormone/blood ; Adrenocorticotropic Hormone/metabolism ; Animals ; Corticosterone/blood ; Hypothalamo-Hypophyseal System/drug effects ; Hypothalamo-Hypophyseal System/pathology ; Male ; Nerve Tissue Proteins/antagonists & inhibitors ; Nerve Tissue Proteins/metabolism ; Neurons/drug effects ; Neurons/metabolism ; Neurons/pathology ; Paraventricular Hypothalamic Nucleus/drug effects ; Paraventricular Hypothalamic Nucleus/metabolism ; Paraventricular Hypothalamic Nucleus/pathology ; Pituitary-Adrenal System/drug effects ; Pituitary-Adrenal System/pathology ; Rats ; Rats, Wistar ; Receptors, Serotonin/chemistry ; Restraint, Physical ; Serotonin Antagonists/pharmacology ; Stress, Physiological/drug effects ; Stress, Psychological/pathology ; Stress, Psychological/prevention & control ; Time Factors

Serotonin (5-HT) modulates the hypothalamic-pituitary-adrenal (HPA) axis response to stress. We examined the effect of chronic restraint stress (CRS; 20 min/day) as compared to control (CTRL) conditions for 14 days, on: 1) restraint-induced ACTH and corticosterone (CORT) secretion in rats pretreated with vehicle or SB-656104 (a 5-HT₇ receptor antagonist); 2) 5-HT₇ receptor-like immunoreactivity (5-HT₇-LI) and protein in the hypothalamic paraventricular nucleus (PVN) and adrenal glands (AG); 3) baseline levels of 5-HT and 5-hydroxyindolacetic acid (5-HIAA), and 5-HIAA/5-HT ratio in PVN and AG; and 4) 5-HT-like immunoreactivity (5-HT-LI) in AG and tryptophan hydroxylase (TPH) protein in PVN and AG. On day 15, animals were subdivided into Treatment and No treatment groups. Treatment animals received an i.p. injection of vehicle or SB-656104; No Treatment animals received no injection. Sixty min later, Treatment animals were either decapitated with no further stress (0 min) or submitted to acute restraint (10, 30, 60 or 120 min); hormone serum levels were measured. No Treatment animals were employed for the rest of measurements. CRS decreased body weight gain and increased adrenal weight. In CTRL animals, acute restraint increased ACTH and CORT secretion in a time of restraint-dependent manner; both responses were inhibited by SB-656104. Exposure to CRS abolished ACTH but magnified CORT responses to restraint as compared to CTRL conditions; SB-656104 had no effect on ACTH levels but significantly inhibited sensitized CORT responses. In CTRL animals, 5-HT₇-LI was detected in magnocellular and parvocellular subdivisions of PVN and sparsely in adrenal cortex. Exposure to CRS decreased 5-HT₇-LI and protein in the PVN, but increased 5-HT₇-LI in the adrenal cortex and protein in whole AG. Higher 5-HT and 5-HIAA levels were detected in PVN and AG from CRS animals but 5-HIAA/5-HT ratio increased in AG only. Finally, whereas 5-HT-LI was sparsely observed in the adrenal cortex of CTRL animals, it strongly increased in the adrenal cortex of CRS animals. No TPH protein was detected in AG from both animal groups. Results suggest that CRS promotes endocrine disruption involving decreased ACTH and sensitized CORT responses to acute restraint. This phenomenon may be associated with increased function and expression of 5-HT₇ receptors as well as 5-HT turnover in AG.
(Copyright © 2013 Elsevier Ltd. All rights reserved.)

Neuropsychopharmacology. 1999 Sep;21(3):352-67. (PMID: 10457532)
J Neurochem. 1998 Sep;71(3):1271-9. (PMID: 9721753)
Neuropharmacology. 2006 Jun;50(7):824-33. (PMID: 16504218)
J Neuroendocrinol. 2006 May;18(5):330-8. (PMID: 16629831)
Am J Physiol. 1998 Dec;275(6):R1928-38. (PMID: 9843882)
Neuroendocrinology. 1992 Dec;56(6):797-802. (PMID: 1369587)
Physiol Behav. 1994 Apr;55(4):747-53. (PMID: 8190805)
Ann N Y Acad Sci. 2008 Dec;1148:349-59. (PMID: 19120128)
Neurosci Lett. 2004 Sep 9;367(3):313-6. (PMID: 15337256)
Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E965-73. (PMID: 16772325)
J Endocrinol. 1982 May;93(2):151-60. (PMID: 6979602)
J Clin Endocrinol Metab. 2006 Nov;91(11):4578-86. (PMID: 16954157)
Free Radic Res. 2010 Feb;44(2):171-80. (PMID: 19886753)
Neuroscience. 2006;138(4):1067-81. (PMID: 16431027)
Methods Enzymol. 1989;172:3-17. (PMID: 2747532)
Mol Pharmacol. 1995 Jan;47(1):99-103. (PMID: 7838138)
Exp Neurol. 2008 Apr;210(2):458-66. (PMID: 18177641)
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):435-49. (PMID: 19302828)
Anal Biochem. 1981 Apr;112(2):223-31. (PMID: 6167177)
J Neuroendocrinol. 1999 Apr;11(4):283-90. (PMID: 10223282)
Neuroendocrinology. 2000 Aug;72(2):114-25. (PMID: 10971146)
Physiol Behav. 2006 Oct 30;89(3):373-8. (PMID: 16899260)
Neuroscience. 2004;124(4):901-11. (PMID: 15026130)
Psychoneuroendocrinology. 1999 Apr;24(3):345-61. (PMID: 10101738)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
Neuroscience. 1983 Dec;10(4):1443-53. (PMID: 6363969)
Endocrinology. 2008 Feb;149(2):818-26. (PMID: 18039788)
Neuroscience. 1992;46(2):495-500. (PMID: 1371854)
Behav Neurosci. 1990 Feb;104(1):28-36. (PMID: 2156523)
J Neuroendocrinol. 2002 Oct;14(10):788-95. (PMID: 12372003)
Neurosci Biobehav Rev. 1986 Fall;10(3):245-50. (PMID: 3774244)
Neurosci Lett. 1988 Oct 31;93(1):19-22. (PMID: 3211367)
Psychopharmacology (Berl). 2009 Oct;206(3):345-54. (PMID: 19649616)
Brain Res Bull. 1993;32(6):567-72. (PMID: 8221154)
Endocrinology. 1998 Feb;139(2):579-87. (PMID: 9449628)
N Engl J Med. 1986 May 22;314(21):1329-35. (PMID: 3010108)
Behav Brain Res. 2000 Sep;114(1-2):175-81. (PMID: 10996058)
Histochemistry. 1987;86(6):541-9. (PMID: 3497137)
Hum Psychopharmacol. 2001 Jan;16(1):23-27. (PMID: 12404594)
Brain Res Mol Brain Res. 1997 Apr;45(1):182-6. (PMID: 9105690)
Endocrinology. 1999 Aug;140(8):3623-32. (PMID: 10433220)
Am J Physiol. 1997 Aug;273(2 Pt 1):E363-8. (PMID: 9277390)
J Neuroendocrinol. 2010 Feb;22(2):92-101. (PMID: 20002965)
Neuroendocrinology. 1985 Sep;41(3):230-6. (PMID: 2413384)
Psychoneuroendocrinology. 1990;15(5-6):317-28. (PMID: 1966300)
J Endocrinol. 1989 May;121(2):253-60. (PMID: 2547005)
Physiol Behav. 1990 Jun;47(6):1117-24. (PMID: 2395915)
J Neurochem. 1997 Jun;68(6):2604-9. (PMID: 9166758)
Neurosci Lett. 1998 Feb 27;243(1-3):17-20. (PMID: 9535102)
J Physiol. 1998 Jul 15;510 ( Pt 2):605-14. (PMID: 9706007)
J Physiol Pharmacol. 2009 Jun;60(2):83-8. (PMID: 19617650)
Br J Pharmacol. 2003 Jun;139(4):705-14. (PMID: 12812993)
Endocrinology. 2003 Dec;144(12):5249-58. (PMID: 12960031)
Int J Dev Neurosci. 2003 May;21(3):133-43. (PMID: 12711351)
Neuroscience. 1996 Feb;70(4):963-88. (PMID: 8848177)
Neurosci Lett. 2001 Aug 31;309(3):141-4. (PMID: 11514061)
J Chem Neuroanat. 2001 Jan;21(1):63-73. (PMID: 11173221)
Pharmacol Biochem Behav. 2008 Nov;91(1):170-5. (PMID: 18675292)
Science. 2003 Jan 3;299(5603):76. (PMID: 12511643)
Endocr Rev. 1998 Apr;19(2):101-43. (PMID: 9570034)
Psychopharmacology (Berl). 2001 Jun;156(1):73-8. (PMID: 11465636)
Brain Res. 1993 May 21;611(2):330-2. (PMID: 8334526)
Neuroendocrinology. 1983;36(3):165-86. (PMID: 6601247)
Neuropsychopharmacology. 2011 May;36(6):1275-88. (PMID: 21326194)
Int Immunopharmacol. 2002 Mar;2(4):487-97. (PMID: 11962728)
Proc Natl Acad Sci U S A. 1984 Mar;81(6):1883-7. (PMID: 6369332)
J Clin Endocrinol Metab. 1999 May;84(5):1729-36. (PMID: 10323408)
Int J Dev Neurosci. 2012 Feb;30(1):19-23. (PMID: 22027619)
Behav Brain Res. 2006 Dec 15;175(2):408-14. (PMID: 17069898)
Brain Res. 1983 Oct 31;277(2):355-60. (PMID: 6357352)
Neuroendocrinology. 1997 May;65(5):360-8. (PMID: 9158068)
Biol Psychiatry. 1995 Mar 15;37(6):383-93. (PMID: 7772647)
Brain Res Bull. 2004 Jul 15;63(6):521-30. (PMID: 15249118)
Endocrinology. 1995 Dec;136(12):5745-50. (PMID: 7588332)
Methods Enzymol. 1983;103:368-76. (PMID: 6366460)
J Clin Endocrinol Metab. 2005 May;90(5):2843-50. (PMID: 15705918)
Endocr Res. 1996 Nov;22(4):577-8. (PMID: 8969914)
Cell Mol Neurobiol. 2008 May;28(3):331-42. (PMID: 18197473)
Ann N Y Acad Sci. 2003 Dec;1007:367-78. (PMID: 14993070)
J Neuroendocrinol. 2002 May;14(5):403-10. (PMID: 12000546)
Psychopharmacology (Berl). 1997 Apr;130(4):368-74. (PMID: 9160853)
J Endocrinol. 1976 Apr;69(1):1-10. (PMID: 5568)
Eur Neuropsychopharmacol. 2009 Mar;19(3):215-28. (PMID: 19147333)
Neuroscience. 1999;94(4):1313-22. (PMID: 10625069)
Bioorg Med Chem Lett. 2002 Nov 18;12(22):3341-4. (PMID: 12392747)
Physiol Behav. 2004 Jun;81(4):557-68. (PMID: 15178148)
J Neuroendocrinol. 2007 Aug;19(8):632-42. (PMID: 17620105)
Physiol Behav. 2004 Jun;81(4):545-55. (PMID: 15178147)
Mol Pharmacol. 1999 Sep;56(3):552-61. (PMID: 10462543)
Brain Behav Immun. 1999 Sep;13(3):225-39. (PMID: 10469524)
Naunyn Schmiedebergs Arch Pharmacol. 2002 Oct;366(4):357-67. (PMID: 12237750)
Horm Behav. 2003 Jan;43(1):60-6. (PMID: 12614635)
Trends Neurosci. 2008 Sep;31(9):464-8. (PMID: 18675469)
Eur J Pharmacol. 1998 Apr 10;346(2-3):261-6. (PMID: 9652368)

R01 TW006622 United States TW FIC NIH HHS; 5R01TW006622 United States TW FIC NIH HHS

0 (5-HT(7) receptor, rat)
0 (Nerve Tissue Proteins)
0 (Receptors, Serotonin)
0 (Serotonin Antagonists)
9002-60-2 (Adrenocorticotropic Hormone)
W980KJ009P (Corticosterone)

Date Created: 20130402 Date Completed: 20140110 Latest Revision: 20240323

20240323

PMC3838668

10.1016/j.neuropharm.2013.03.013

23542440